Cost evaluation of patients with severe sepsis in intensive care units;La valutazione dei costi pazienti affetti da sepsi severa in terapia intensiva

Minerva Anestesiologica

Volumn 70, Issue 6, 2004, Pages 453-471

  Piacevoli, Q ^a   Palazzo, F ^b   Azzeri, F ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; DROTRECOGIN; PLACEBO;

ARTICLE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE SEVERITY; ECONOMIC EVALUATION; EUROPE; EVIDENCE BASED MEDICINE; GOOD CLINICAL PRACTICE; HEALTH CARE COST; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; ITALY; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SEPSIS; SEPTIC SHOCK;

EUROPE; HEALTH CARE COSTS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; ITALY; SEPSIS; WORLD HEALTH;

EID: 4344717927     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Chalfin DB. Evidence-based medicine and cost-effectiveness analysis. Crit Care Med 1998;14:525-37. <>>⌋frt Chalfin DB. Evidence-based medicine and cost-effectiveness analysis. Crit Care Med 1998;14:525-37.
2. Bone RC. Economic analysis of the intensive care unit: a dilemma. Crit Care Med 1995;23:805.
3. Chalfin DB. Analysis of cost-effectiveness in intensive care: an overview of methods and a review of applications to problems in critical care medicine. Curr Opin Anesthesiol 1996;9:129-33.
4. Cullen DJ. Results and costs of intensive care. Anesthesiology 1977;47:203-16.
5. Gyldmark M. A review of cost studies of intensive care units: problems with the cost concept. Crit Care Med 1995;23:964-72.
6. Halpern NA, Bettes L, Greenstein R: Federal and nationwide intensive care units and health care costs: 1986-1992. Crit Care Med 1994;19:2001-7.
7. Knaus WA, Wagner DP, Zimmerman JE. Variations in mortality and lenght of stay in intensive care units. Ann Intern Med 1993;118:753-61.
8. Dawson JA. Admission, discharge, and triage in critical care. Crit Care Clin 1993;9:555-74.
9. Evidence Based Medicine Working Group. Evidence Based Medicine: a new approach to teaching the practice of medicine. JAMA 1992;268:2420-5.
10. Finkler SA. The distinction between cost and charges. Ann Intern Med 1992;96:102-7.
11. Birch S, Gafni A. Cost effectiveness/utility analysis: do current decision rules lead as to where we wont to be? J Health Econ 1992;11:279-96.
12. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990;113:147-54.
13. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med 1994;331:669-70.
14. Drummond MF. Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1987.
15. Drummond MF, Richardson WS, O'Brien B. User's guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A: Are the results of the study valid? JAMA 1997;277:1552-7.
16. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
17. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA, 1996;276:1172-7.
18. Schapira DV, studnicki J, Bradham DD, Wolff P, Jarrett A. Intensive care, survival, and expense of treating critically ill cancer patients. JAMA 1993;269:783-6.
19. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA 1996;276:1339-41.
20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. The recommendations of the Panel on Cost-Effectiveness Analysis in health and medicine. JAMA 1996;276;1253-8.
21. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Costeffectiveness and cost-benefit analyses in the literature. Are the methods being used correctly? Ann Inter Med 1992;116:238-44.
22. O'Brien B, Heyland DK, Richardson WS, Levine M, Drummond MF. User's guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? JAMA 1997;277:1802-6.
23. Gafni A, Birch S. Equity considerations in utility-based measure of health outcomes in economic appraisals: an adjustment algorithm. J Health Econ 1991;10:329-421.
24. Kirton OC, Civetta JC, Hudson-Civetta J RN. Cost effectiveness in the Intensive Care Unit. Surg Clin North Am 1996;76:175-200.
25. Heyland DK, Gafni A, Kernerman P, Keenan S, Chalfin D. How to use an economic evaluation. Crit Care Med 1999;27;1195-202.
26. Heyland D, Kernerman P, Gafni A, Cook DJ. Economic evaluations in the critical care literature: do they help us to improve the efficiency of our unit? Crit Care Med 1996;24:1591-8.
27. Heyland DK, Konopad E, Noseworthy T, Johnston R, Gafni A. Is it "worthwhile" to continue treating patients with a prolonged stay (>14 days) in the ICU? An economic analysis. Chest 1998; 114:192-8.
28. Center for Disease Control. Increase in National Hospital Discharge Survey Rates for Setticemia - United States, 1979-1987. JAMA 1990;263:937-8.
29. Bone C, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA et al. American College of Chest Physicians/ Society of critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-55.
30. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainant JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
31. Manns BJ, Lee H, Doig J, Johnston D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N. Engl J Med 2002;347:993-1000.
32. Davies A, Green C, Hutton J. Severe sepsis and septic shock: a European estimate of the cost of illness in ICUs. Abstract presented at 14th Congress of the European Society of Intensive Care Medicine, 30 September-3 October 2001, Geneva, Switzerland.
33. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999;27:1760-7.
34. Moerer O, Schmid A, Hofmann M, Herklotz A, Reinhart K, Werdan K et al. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 2002;28:1440-6.
35. Neilson AR, Schneider H, Chinn C, Clouth J, Burchardi H. The PROWESS Economic Team. Cost-effectiveness of Drotrecogin Alfa (Activated) for the treatment of severe sepsis in Germany. Eur J Health Econom 2002; 3:77-82.
36. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
37. Lucioni C, Currado J, Langer M, Mazzi S. I costi della sepsi in Italia. Farmacoeconomia e Percorsi Terapeutici 2001;2:139-48.
38. Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A et al. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 1995; 21(Suppl 2):S244-9.
39. Cavallo MC, Lazzaro C, Tabacchi M, Langer M, Salvo I, Serra G et al. Il costo del reparto di terapia intensiva in Italia: risultati da un'indagine empirica su un campione di 12 centri. Minerva Anestesiol 2001;67:41-53.
40. Del Bufalo P, Gobbi B, Todaro S. Il Sole 24 Ore Sanità, 24-30 Dec 2002;15-20.
41. Agenzia per i Servizi Sanitari Regionali. Dati di bilancio e SDO relativi al 2000 delle Aziende Sanitarie Nazionali. Pubblicazione 2002.
42. Lucioni C, Mazzi S, Christopher C. Il trattamento di pazienti con sepsi grave mediante Drotrecogin alfa: una valutazione economica con riferimento all'Italia. Farmacoeconomia e percorsi terapeutici 2001;3:179-85.
43. Drabinski A, Williams G, Formica C. Observational evaluation of Health State Utilities among a cohort of sepsis patients. Value Health 2001;4:128-30.
44. Messori A, Trippoli S. La farmacoeconomia come disciplina scientifica: panoramica delle principali metodologie ed esempi. Giornale di Farmacoeconomia 1998;2:176-89.